Placebo effects: Issues for clinical practice in psychiatry and medicine

Psychosomatics

Volumn 37, Issue 4, 1996, Pages 315-326

  Straus, Joshua L ^a,b   Von Ammon Cavanaugh, Stephanie ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

CLINICAL PRACTICE; DOCTOR PATIENT RELATION; DRUG USE; HUMAN; MEDICINE; PRESCRIPTION; PSYCHIATRY; REVIEW;

EID: 8944247745     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0033-3182(96)71544-X     Document Type: Review

References (121)

1. Spiro H: Doctors, Patients, and Placebos. New Haven, Yale University Press, 1986, pp. 10-11
2. Bok S: The ethics of giving placebos. Sci Am 1974; 231:17-23
3. Howells JG (ed): The placebo response, in Modern Perspectives in World Psychiatry, Vol 2, Edinburgh, Scotland, Oliver and Boyd, 1968
4. Pepper OHP: A note on the placebo. American Journal of Pharmacy 1945; 117:409-412
5. Shapiro AK: A contribution to a history of the placebo effect. Behav Sci 1960; 5:398-430
6. Hollingsworth HL: The influence of caffeine on mental and motor efficiency. Arch Psychol 1912; 22:1-166
7. Beecher HK, Keats AS, Mosteller F, et al: The effectiveness of oral analgesics (morphine, codeine, acetylsalicylic acid) and the problem of placebo "reactors" and "nonreactors." Journal of Pharmacology and Experimental Therapeutics 1953; 109:393-400
8. Lasagna L, Mosteller F, von Felsinger JM, et al: A study of the placebo response. Am J Med 1954; 16:770-779
9. Shapiro AK, Morris LA: The placebo effect in medical and psychological therapies, in Handbook of Psychotherapy and Behavior Change: An Empirical Analysis, 2nd Edition, edited by Garfield SL, Bergin AE. New York, Wiley, 1978, pp. 371-372
10. Gótzsche PC: Is there logic in the placebo? Lancet 1994; 344: 925-926
11. Grünbaum A: The placebo concept in medicine and psychiatry. Psychol Med 1986; 16:19-38
12. Gilman AG, Goodman LS, Rall TW, et al (eds): The Pharmacological Basis of Therapeutics, 7th Edition, New York, Macmillan, 1985, pp. 680-689, 892-896
13. Wolf S, Pinsky RH: Effects of placebo administration and occurrence of toxic reactions. JAMA 1954; 155:339
14. Coryell W, Noyes R: Placebo response in panic disorder. Am J Psychiatry 1988; 145:1138-1140
15. Quitkin FM, McGrath PJ, Rabkin JG, et al: Different types of placebo response in patients receiving antidepressants. Am J Psychiatry 1991; 148:197-203
16. Cobb LA, Thomas GI, Dillard DH, et al: An evaluation of internal mammary artery ligation by a double-blind technique. N Engl J Med 1959; 260:1115-1118.
17. Dimond EG, Kittle CF, Crockett JE: Comparison of internal mammary ligation and sham operation for angina pectoris. Am J Cardiol 1960; 5:483-486
18. Remington G, Fornazzari L, Sethna R: Placebo response in refractory tardive akathisia. Can J Psychiatry 1993; 38:248-250
19. Dunphy BC, Kay R, Robinson JN, et al: The placebo response of subfertile couples to attending a tertiary referral centre. Fertil Steril 1990; 54:1072-1075
20. Garcia CR, Freeman EW, Rickels K, et al: Behavioral and emotional factors and treatment responses in a study of anovulatory infertile women. Fertil Steril 1985; 44:478-483
21. Aitchison R, Carter R, Paterson P, et al: Is the treatment of urgency incontinence a placebo response? Br J Urol 1989; 64:478-480
22. Wolf S: Effects of suggestion and conditioning on the action of chemical agents in human subjects - the pharmacology of placebos. J Clin Invest 1950; 29:100
23. Lasagna L, Laties VG, Dohan JL: Further studies on the "pharmacology" of placebo administration. J Clin Invest 1958; 37:533-537
24. Joyce CRB: Nonspecific aspects of treatment from the point of a clinical pharmacologist, in Nonspecific Aspects of Treatment, edited by Shepher M, Sartorius N. Toronto, Ontario, Canada, Huber, pp. 57-94
25. Kleijnen J, de Craen AJM, Everdingen JV, et al: Placebo effect in double-blind clinical trials: a review of interactions with medications. Lancet 1994; 344:1347-1349
26. Buckalew LW, Coffield KE: An investigation of drug expectancy as a function of capsule color and size and preparation form. J Clin Psychopharmacol 1982; 2:245-248
27. Blackwell B, Bloomfield SS, Buncher CR: Demonstration to medical students of placebo responses and non-drug factors. Lancet 1972; 1:1279-1282
28. Schapira K, McClelland HA, Griffiths NR, et al: Study of the effects of tablet colour in the treatment of anxiety states. BMJ 1970; 2:446-449
29. Quitkin FM, McGrath PJ, Rabkin JG, et al: Different types of placebo response in patients receiving antidepressants. Am J Psychiatry, 1991; 148:197-203
30. Turkkan JS, Brady JV: Mediational theory of the placebo effect, in Placebo: Theory, Research, and Mechanisms, edited by White L, Tursky B, Schwartz G. New York, Guilford Press, 1985, pp. 431-437
31. McDonald D, Stern J, Hahn W: Classical heart rate conditioning in the rat. J Psychosom Res 1963; 7:97-106
32. Turkkan JS, Brady JV, Harris AH: Animal studies of stressful interactions: a behavioral-physiological overview, in Handbook of Stress, edited by Goldberger L, Breznitz S. New York, Macmillan, 1982
33. Suchman AL, Ader R: Classic conditioning and placebo effects in crossover studies. Clin Pharmacol Ther 1992; 52:372-377
34. Wickramasekera I: A conditioned response model of the placebo effect: predictions from the model, in Placebo: Theory, Research, and Mechanisms, edited by White L, Tursky B, Schwartz G. New York, Guilford Press, 1985, pp. 431-437
35. Shapiro D, Surwit RS: Operant conditioning: a new theoretical approach, in Psychosomatic Medicine: Current Trends and Clinical Applications, edited by Lipowski ZJ, Lipsitt DR, Whybrow PC. New York, Oxford University Press, 1977, pp. 68-78
36. Frankel FH: Hypnosis in psychosomatic medicine, in Psychosomatic Medicine: Current Trends and Clinical Applications, edited by Lipowski ZJ, Lipsitt DR, Whybrow PC. New York, Oxford University Press, 1977, pp. 366-376
37. Tepperman J, Tepperman HM: Metabolic and Endocrine Physiology. Chicago, IL, Year Book Medical Publishers, 1987, pp. 92-93
38. Insel TR: Oxytocin-a neuropeptide for affiliation: evidence from behavioral, receptor autoradiographic, and comparative studies. Psychoneuroendocrinology 1992; 17:3-35
39. Thakore JH, Dinan TG: Effect of fluoxetine on dexamethasone-induced growth hormone release in depression: a double-blind, placebo controlled study. Am J Psychiatry 1995; 152:616-618
40. Bootzin RR: The role of expectancy in behavior change, in Placebo: Theory, Research, and Mechanisms, edited by White L, Tursky B, Schwartz G. New York, Guilford Press, 1985, pp. 431-437
41. Fillmore M, Vogel-Sprott L: Expected effect of caffeine on motor performance predicts the type of response to placebo. Psychopharmacology 1992; 106:209-214
42. Greist JH, Marks IM, Berlin F, et al: Avoidance versus confrontation of fear. Behavior Therapy 1980; 11:1-14
43. Twemlow SW, Gabbard GO: The illusion that heals: a tentative explication of the placebo response. Journal of Holistic Medicine 1985; 7:89-96
44. Winnicott DW: Transitional objects and transitional phenomena, in Winnicott: Collected Papers. New York, Basic Books, 1958
45. Brody H: Placebo effect, in Placebo: Theory, Research, and Mechanisms, edited by White L, Tursky B, Schwartz G. New York, Guilford Press, 1985, pp. 39-49
46. Hahn RA: A sociocultural model of illness and healing, in Placebo: Theory, Research, and Mechanisms, edited by White L, Tursky B, Schwartz G. New York, Guilford Press, 1985, pp. 167-195
47. Coronary Drug Project Group: Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980; 303:1038-1041
48. Smith TC, Thompson TL: The inherent, powerful therapeutic value of a good physician-patient relationship. Psychosomatics 1993; 3:166-170
49. Thomas KB: General practice consultations: is there any point in being positive? BMJ 1987; 294:1200-1202
50. Suedfeld P: The subtractive expectancy placebo procedure: a measure of nonspecific factors in behavioural interventions. Behav Res Ther 1984; 22:159-164
51. Critchley EMR, Mitchell, JD: Explanation and management of neurological disability. BMJ 1987; 294:1203-1205
52. Uhlenhuth EH, Canter A, Neustadt JO, et al: The symptomatic relief of anxiety with meprobamate, phenobarbital, and placebo. Psychiatry 1959; 115:905-910
53. Beckman HB, Markakis KM, Suchman AL, et al: The doctor-patient relationship and malpractice: lessons from plaintiff depositions. Arch Intern Med 1994; 154:1365-1370
54. Niaura R, Goldstein MG: Cardiovascular Disease, Part II, in Psychological Factors Affecting Medical Conditions, edited by Stoudemire A. Washington, DC, American Psychiatric Press, 1995, pp. 39-56
55. Lex BW: Voodoo death: new thoughts on an old explanation, in Culture, Disease, and Healing, edited by Landy D. New York, Macmillan, 1977, pp. 327-331
56. Rosenzweig P, Brohier S, Zipfel A: The placebo effect in healthy volunteers: influence of experimental conditions on the adverse events profile during phase I studies. Clin Pharmacol Ther 1993; 54:578-583
57. Medical Economics: Physicians' Desk Reference. Montvale, NJ, Medical Economics, 1995, p. 947
58. Chaput de Saintonge, Herxheimer A: Harnessing placebo effects in health care. Lancet 1994; 344:995-998
59. Gowdey CW, Hamilton JT, Philb RB: A controlled clinical trial using placebos in normal subjects: a teaching exercise. Can Med Assoc J 1967; 96:1317-1322
60. Ader R: Conditioned immunopharmacologic effects in animals: implications for a conditioning model of pharmacotherapy, in Placebo: Theory, Research, and Mechanisms, edited by White L, Tursky B, Schwartz G. New York, Guilford Press, 1985, pp. 306-323
61. Levine J, Gordon NC, Fields HL: The mechanism of placebo analgesia. Lancet 1978; 2:654-657
62. Beecher HK: Increased stress and effectiveness of placebos and active drugs. Science 1960; 132:91-92
63. Voudouris NJ, Peck CL, Coleman G: Conditioned placebo responses. J Pers Soc Psychol 1985; 48:47-53
64. Evans FJ: The placebo response in pain reduction, in Advances in Neurology, Vol 4: Pain, edited by Bonica JJ. New York, Raven Press, 1974
65. Grevert P, Goldstein A: Placebo analgesia, naloxone and the role of endogenous opioids, in Placebo: Theory, Research, and Mechanisms, edited by White L, Tursky B, Schwartz G. New York, Guilford Press, 1985, pp. 332-350
66. Wolff HG, DuBois F, Gold H: Cornell conferences on therapy: the use of placebos in therapy. New York State Journal of Medicine 1946; 46:718-727
67. Wolf S: Effects of suggestion and conditioning on the action of chemical agents in human subjects-the pharmacology of placebos. J Clin Invest 1950; 29:100-109
68. Beecher HK: Experimental pharmacology and measurement of the subjective response. Science 1952; 116:157
69. Gruber CM: Interpreting medical data. Arch Intern Med 1956; 98:767-773
70. Rickels K: Use of placebo in clinical trials. Psychopharmacol Bull 1986; 22:19-24
71. Ross OB Jr: Use of controls in medical research. JAMA 1951; 145:72
72. Ney PG, Collins C, Spensor C: Double-blind: double talk or are there ways to do better research? Medical Hypotheses 1986; 21:119-126
73. Thomson R: Side effects and placebo amplification. Br J Psychiatry 1982;140: 64-68
74. Omer H, London P: Signal and noise in psychotherapy: the role and control of nonspecific factors. Br J Psychiatry 1989; 155:239-245
75. Stewart J: Placebos in evaluating light therapy for seasonal affective disorder. Psychopharmacol Bull 1990; 26:525-526
76. Young MA, Fogg LF: Predicting response to treatment: differentiating active factor and nonspecific effects. Stat Med 1990; 9:253-261
77. Rosenthal R: Meta-analysis: a review. Psychosom Med 1991; 53:247-271
78. Whitney C, Von Korff M: Regression to the mean in treated versus untreated chronic pain. Pain 1992; 50:281-285
79. Hutchison BG: Critical appraisal of review articles. Can Fam Physician 1993; 39:1097-1102
80. Streiner DL: Using meta-analysis in psychiatric research. Can J Psychiatry 1991; 36:357-362
81. Beecher HK: The powerful placebo. JAMA 1955; 176:1102-1107
82. Modell W, Garrett M: Interactions between pharmacodynamic and placebo effects in drug evaluations in man. Nature 1960; 185:538-539
83. Sheline YI, Black KJ, Bardgett ME, et al: Platelet-binding characteristics distinguish placebo responders from nonresponders in depression. Neuropsychopharmacology 1995; 12:315-322
84. Karasu TB: The specificity versus nonspecificity dilemma: toward identifying therapeutic change agents. Am J Psychiatry 1986; 143:687-695
85. Simon H: Sciences of the Artificial, 2nd Edition. Cambridge, MA, MIT Press, 1981, pp. 36-37
86. Lamas GA, Pfeffer MA, Hamm P, et al: Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? N Engl J Med 1992; 327:241-247
87. Fox R: Clinical trials and clinical practice (editorial). Lancet 1993; 342:877-878
88. Bigger JT: Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment. Am J Cardiol 1990; 65:3D-10D
89. The Cardiac Arrhythmia Suppression Trial II Invesigators: effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327:227-233
90. Coplen SE, Antman EM, Berlin JA, et al: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation 1990; 82:1106-1116
91. Johnson AG: Surgery as a placebo. Lancet 1994; 344:1140-1142
92. Cowley DS: Generalized anxiety disorder, in Current Psychiatric Therapy, edited by Dunner DL. Philadelphia, PA, WB Saunders, 1993, pp. 263-269
93. Hardy J (ed): Textbook of Surgery. Philadelphia, PA, Lippincott, 1983, pp. 1184-1185
94. Shenoy RS, Sadler AG, Goldberg SC, et al: Effects of a 6-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics. J Clin Psychopharmacol 1981;1:141-145
95. Newton JE, Cannon DJ, Couch, et al: Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients, J Clin Psychiatry 1989; 50:132-135
96. Schooler NR: Maintenance medication for schizophrenia: strategies for dose reduction. Schizophr Bull 1991; 17:311-324
97. Sabiston DL (ed): Textbook of Surgery, 13th Edition. Philadelphia, PA, WB Saunders, 1986, pp. 529-533
98. Scott JR, Disaia PJ, Hammand CG: Danforth's Obstetrics and Gynecology, 7th Edition. Philadelphia, PA, Lippincott, 1994, p. 676
99. Kase NG, Weingold AB: Principles and Practice of Clinical Gynecology, 2nd Edition. New York, Churchill-Livingston, 1990, pp. 246, 555-556
100. Waddell, G: A new clinical model for the treatment of low-back pain. Spine 1987; 12:632-644
101. Gilbert JR, Taylor DW, Hildebrand A: Clinical trial of common treatments for low back pain in family practice. BMJ 1985; 291:791-794
102. Herz MI, Glazer WM, Mosten MA, et al: Intermittent vs maintenance medication in schizophrenia. Arch Gen Psychiatry, 1991; 48:333-339
103. Ravnikar VA, Chen E: Hysterectomies: where are the indications? Obstet Gynecol Clin North Am 1994; 21:405-411
104. Fox R: On stopping a trial before its time (editorial). Lancet 1993; 342:1311-1312
105. Concorde Coordinating Committee: Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343:871-881
106. Darbyshire J: Perspectives in drug therapy of HIV infection. Drugs 1995; 49(suppl):1-3
107. Caliendo AM, Hirsch MS: Combination therapy for infection due to human immunodeficiency virus type 1. Clin Infect Dis 1994; 18:516-524
108. MacIlwain C: Activists now urge caution on approval of new AIDS drug. Nature 1993; 365:378
109. Roberts J: U.S. AIDS activists urge caution on new anti-HIV drags. BMJ 1994; 309:757
110. Rothman KJ, Michels, KB: The continuing unethical use of placebo controls. N Engl J Med 1994; 331:394-398
111. Lasagna L: The Helsinki Declaration: timeless guide or irrelevant anachronism. J Clin Psychopharmacol 1995; 15:96-98
112. Sachar DB: Placebo-controlled trials in gastroenterology: a position paper of the American College of Gastroenterology. Am J Gastroenterol 1984; 79:913-917
113. American Academy of Pediatrics Committee on Drugs: Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics 1977; 60:90-101
114. Janicak PG, Davis JM, Preskorn SH, et al: Principles and Practice of Psychopharmacotherapy. Baltimore, MD, Williams & Wilkins, 1993, p. 105
115. Rein W, Morselli PL: Patient sampling in anxiety studies: factors influencing response rate. Eur Psychiatry 1994; 9:137-139
116. Mavissakalian MR, Jones B, Olson S: Absence of placebo response in obsessive-compulsive disorder. J Nerv Ment Dis 1990; 178:268-270
117. Thoren P, Asberg M, Cronholm B, et al: Clomipramine treatment of obsessive-compulsive disorder. Arch Gen Psychiatry, 1980; 37:1281-1285
118. Perse TL, Greist JH, Jefferson JW, et al: Fluvoxamine treatment of obsessive-compulsive disorder. Am J Psychiatry 1987; 144:1543-1548
119. Moerman DE: General medical effectiveness and human biology: placebo effects in the treatment of ulcer disease. Medical Anthropology Quarterly 1983; 14:13-16
120. Goadsby PJ, Zagami AS, Donnan GA, et al: Oral sumatriptan in acute migraine. Lancet 1991; 338:782-783
121. Fedele L, Marchini M, Acaia B, et al: Dynamics and significance of placebo response in primary dysmenorrhea. Pain 1989; 36:43-47